Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2018-04-30 | John G. Cooper, age 59, has been a director since September 2017. Mr. Cooper is currently founder and principal of JGC Advisors, providing corporate development and financial advisory services to emerging life science companies. |
| 2019-04-30 | Mr. Cooper, age 60, has been a director since September 2017. He serves as Chairman of the Audit Committee. 2018 Director Compensation table shows $185,000 fees earned in cash and $101,189 option awards totaling $286,189. |
| 2020-04-20 | John G. Cooper has been a director and Chair of the Audit Committee since September 2017. ... We have an Audit Committee which is currently comprised of Messrs. Cooper (Chairman), McLaughlin and Ravich. ... We have a Governance and Nominating Committee which is currently comprised of Mr. McLaughlin (Chairman), Ms. Colleran and Mr. Cooper. ... 2019 Director Compensation ... John Cooper ... Total ($) 288,428. |
| 2021-04-30 | John G. Cooper has been a director and Chair of the Audit Committee since September 2017. ... Mr. Cooper is currently principal of JGC Advisors ... We believe that Mr. Cooper’s extensive executive management, finance and accounting, capital raising, strategic alliance, investor relations and governance experience with public companies in the life sciences industry qualifies him for service as a director and Chair of the Audit Committee of our Company. |
| 2022-04-08 | John G. Cooper(1)(2) 63 Director (1) Member of the Compensation Committee. (2) Member of the Audit Committee. 2021 Director Compensation: Fees Earned or Paid in cash ($) 73,123, Restricted Stock Unit Awards ($) 44,915, Option Awards ($) 42,319, Total ($) 160,357. |
| 2023-04-17 | John G. Cooper has been a director and Chair of the Audit Committee since September 2017. Mr. Cooper is currently principal of JGC Advisors, providing corporate development and financial advisory services to emerging life science companies, and serves on the strategic advisory board of IC Surgical, Inc. From 2001 to 2016, Mr. Cooper was a senior executive for Windtree Therapeutics Inc. (formerly Discovery Laboratories, Inc.), a publicly traded bio pharmaceutical company and the first to receive FDA approval for a synthetic peptide-containing surfactant to address premature infants with respiratory distress syndrome. At Discovery Labs, Mr. Cooper served as president, chief executive officer and a member of the board of directors from 2013 to 2016, president and chief financial officer from 2010 to 2013, executive vice president and chief financial officer from 2002 to 2010 and senior vice president and chief financial officer from 2001 to 2002. Previously, Mr. Cooper served as senior vice president and chief financial officer at Chrysalis International Corporation, a public company providing drug development services to the biopharmaceutical industry, and DNX Corporation, a public life sciences company pioneering transgenic technology for xenotransplantation and biotherapeutic development. Previously, Mr. Cooper served as a financial executive at ENI Diagnostics, Inc., a public life sciences company (acquired by Pharmacia AB) that developed and commercialized the second FDA-approved blood diagnostic test for HIV and a financial analyst at CR Bard, Inc., a public medical device company. Mr. Cooper earned a certified public accountant credential in 1985 and his B.S. in Commerce from Rider University. We believe that Mr. Cooper’s extensive executive management, finance and accounting, capital raising, strategic alliance, investor relations and governance experience with public companies in the life sciences industry qualifies him for service as a director and Chair of the Audit Committee of our Company. |
| 2024-04-15 | John G. Cooper has been a director and Chair of the Audit Committee since September 2017. He served on the Audit Committee and Compensation Committee during 2023. 2023 Director Compensation shows $77,267 fees earned or paid in cash and $65,000 restricted stock unit awards, totaling $142,267. |
| Filing Date | Source Excerpt |
|---|---|
| 2013-04-30 | John G. Cooper has served as a member of our Board and our Chief Executive Officer since January 2013, as our President and Chief Financial Officer since 2010, as Executive Vice President and Chief Financial Officer, from 2002 to 2010, and as Senior Vice President and Chief Financial Officer, from 2001 to 2002. Mr. Cooper brings a deep knowledge of our Company gained from his positions as President and Chief Financial Officer, and his extensive experience in the biotechnology industry. With his extensive knowledge of our Company, our mission and objectives, his participation on the Board is expected to enhance the dialogue and effectiveness of discourse between our Board and our management team. |
| 2014-04-28 | John G. Cooper has served as a member of our Board and our President and Chief Executive Officer since January 2013. He joined our Company in December 2001 and, until March 21, 2014, served as our Chief Financial Officer. Directors who are also employees are not compensated separately for serving on the Board or any of its committees. |
| 2015-04-29 | John G. Cooper, age 56, has served as a member of our Board and our President and Chief Executive Officer since January 2013. ... Directors who are also employees are not compensated separately for serving on the Board or any of its committees. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22